Sylvatica Biotech

Sylvatica Biotech, founded in 2019 and based in San Diego, is a private, pre-revenue biotech company pioneering organ preservation technology. Its lead platform involves supercooling (partial freezing) to significantly extend the preservation time of human organs, most notably livers, as evidenced by peer-reviewed publications in journals like Nature Biotechnology. The company's work, supported by prestigious grants from the NIH and DoD, addresses a massive unmet need in transplantation logistics and has the potential to transform multiple areas of medicine by creating viable organ banks.

Advanced sub-zero organ preservation platform utilizing supercooling and partial freezing techniques. The technology involves treating organs with protective solutions to cool them below 0°C without freezing, dramatically slowing metabolism and degradation to extend viable preservation time from hours to potentially days.

Sylvatica competes with other organ preservation approaches, primarily normothermic machine perfusion (NMP) systems, which keep organs warm and functioning outside the body and are already in clinical use. Traditional static cold storage is the entrenched standard. In the cryopreservation space, other groups are pursuing vitrification at much lower temperatures, but Sylvatica's high-subzero approach is a distinct technical path. The competitive field is small but includes well-funded academic labs and a few private companies.